Project Details
Description
During the last 2.5 decades, I have led clinical efforts to develop novel NK cell immunotherapy strategies to treat
cancer by advancing lab-based discoveries in the areas of natural killer (NK) cell and IL-15 biology. This work
has been supported by a continuously funded and recently renewed NCI P01 (CA111412) grant, now in its 21st
year of funding (through 2026). This P01 will serve as the clinical output for the translational work proposed in
this R35 application. An R35 award will allow me to further pivot my research program to focus on solid tumors.
I started a long-standing NK Cell Program at the University of Minnesota that now includes a team of basic and
translational scientists interested in NK cell immunotherapy. My research group has found that exposure to
cytomegalovirus (CMV) induces a population of NK cells with potent immune and anti-tumor function that are
marked by the expression of the NKG2C activating receptor that recognizes HLA-E, which is overexpressed on
many solid tumor cancers. Our highest impact research during the past 5 years is based on an induced
pluripotent stem cell (iPSC)-derived NK cell platform designed with attributes of naturally occurring CMV-induced
adaptive NK cells. This iPSC platform allows an unlimited number of iPSC gene edits to be performed at the
clonal level for mechanistic studies that will be translated into clinical trials. I have used my expertise in NK cell
development to help develop methods for directed differentiation of iPSCs to the NK cell lineage (termed iNK) at
clinical scale to generate fully functional NK cells for immunotherapy. These iNK cells will be multiplex engineered
to enhance tumor-specific activity and persistence in a hostile “cold” tumor environment. My team, who pioneered
adoptive transfer of allogeneic NK cells in 2005, has the most experience worldwide, having infused >400
haploidentical NK cell products to treat patients with cancer. We have now made a complete transition away
from individual donor blood cell products because of their variability, barriers to gene editing, high cost, and
difficulty exporting to the cancer community. The overarching goal of this R35 OIA is to develop novel
strategies to specifically target solid tumor malignancies by testing new iPSC edits that facilitate homing and
migration, overcome hypoxia, and promote survival after adoptive transfer in patients with solid tumor
malignancies. To enhance the specificity and anti-tumoral activity of our iNK cells, we have developed a camelid
nanobody specific for B7-H3 that serves as the engager of a novel chimeric antigen receptor (CAR). We have
chosen to further study the anti-tumor function of these new CAR iNK cells against two solid tumors (glioblastoma
and prostate cancer) that demonstrate oncogenic dependence on the expression of B7-H3. B7-H3 is not
expressed at the protein level in normal tissues. We will also compare these CAR iNK cells using the same CAR
edited into an iPSC-derived T cell (termed iT). The impact of these investigations is to develop novel off-the-
shelf immune cell therapies with potential to change standards of cancer care.
Status | Active |
---|---|
Effective start/end date | 8/1/23 → 7/31/24 |
Funding
- National Cancer Institute: $928,524.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.